CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 48,551 shares, a growth of 58.7% from the May 14th total of 30,584 shares. Based on an average daily trading volume, of 128,880 shares, the short-interest ratio is presently 0.4 days. Approximately 3.3% of the shares of the company are sold short.

Insider Activity at CNS Pharmaceuticals

In other CNS Pharmaceuticals news, Director Faith L. Charles bought 7,100 shares of CNS Pharmaceuticals stock in a transaction dated Monday, May 18th. The stock was acquired at an average cost of $4.79 per share, with a total value of $34,009.00. Following the completion of the acquisition, the director owned 7,100 shares of the company’s stock, valued at approximately $34,009. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.01% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Armistice Capital LLC acquired a new stake in shares of CNS Pharmaceuticals in the second quarter valued at approximately $335,000. Ikarian Capital LLC acquired a new stake in shares of CNS Pharmaceuticals in the fourth quarter valued at approximately $241,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of CNS Pharmaceuticals in the fourth quarter valued at approximately $71,000. 14.02% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CNS Pharmaceuticals has a consensus rating of “Hold” and an average target price of $20.00.

CNS Pharmaceuticals Stock Down 2.3%

NASDAQ CNSP opened at $4.63 on Wednesday. The stock has a market capitalization of $6.76 million, a P/E ratio of -0.16 and a beta of 3.06. CNS Pharmaceuticals has a 52-week low of $1.90 and a 52-week high of $12.36. The firm has a 50-day moving average price of $4.24 and a 200 day moving average price of $4.60.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($7.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.82) by $1.52.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.